Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

August 1, 2024

https://www.globenewswire.com/news-release/2024/07/31/2921816/0/en/Achieve-Life-Sciences-Announces-FDA-Grants-Breakthrough-Therapy-Designation-to-Cytisinicline-for-the-Treatment-of-E-Cigarette-or-Vaping-Nicotine-Dependence.html

SEATTLE and VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for cytisinicline for nicotine e-cigarette, or vaping, cessation.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.